Skip to main content
Top
Published in: Forensic Science, Medicine and Pathology 4/2018

01-12-2018 | Original Article

The pitfalls of per se thresholds in accurately identifying acute cannabis intoxication at autopsy

Authors: Mary K. Schwerdt, James R. Gill

Published in: Forensic Science, Medicine and Pathology | Issue 4/2018

Login to get access

Abstract

Some laws in the United States define cannabis-impaired driving criteria using various per se language that uses specific concentrations of various cannabinoid compounds to establish driving-under-the-influence (DUI). We hypothesize that there will be decedents whose postmortem toxicology profiles would be considered indicative of an acute cannabinoid intoxication under varying DUI per se laws, despite having survived longer than the expected duration of cannabinoid impairment effects. This study examined decedents in whom quantified cannabis metabolites were detected in Connecticut medical examiner autopsy samples, in which the medically-confined survival interval was longer (4–12 and > 12 h) than the expected duration of cannabinoid impairment effects. Several of the 15 decedents, despite being intubated and/or comatose during the medically-confined period of abstinence, would have exceeded DUI per se limits based upon their toxicology results. The use of drug concentrations alone to equate to an acute cannabis intoxication may result in inappropriate arrest, prosecution, and civil liability.
Literature
1.
go back to reference SAMHSA. Behavioral health trends in the United States: results from the 2014 national survey on drug use and health. Department of Health and Human Services USA; 2015. SAMHSA. Behavioral health trends in the United States: results from the 2014 national survey on drug use and health. Department of Health and Human Services USA; 2015.
2.
go back to reference Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–60.CrossRef Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–60.CrossRef
3.
go back to reference Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R, et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction. 2009;104:2041–8.CrossRef Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R, et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction. 2009;104:2041–8.CrossRef
4.
go back to reference Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7:149–56.PubMedPubMedCentral Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7:149–56.PubMedPubMedCentral
5.
go back to reference Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989;37:273–7.CrossRef Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989;37:273–7.CrossRef
6.
go back to reference Kelly P, Jones R. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992;16:228–35.CrossRef Kelly P, Jones R. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992;16:228–35.CrossRef
7.
go back to reference Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60:631–43.CrossRef Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60:631–43.CrossRef
8.
go back to reference Holland MG, Schwope DM, Stoppacher R, Gillen SB, Huestis MA. Postmortem redistribution of Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Forensic Sci Int. 2011;212:247–51.CrossRef Holland MG, Schwope DM, Stoppacher R, Gillen SB, Huestis MA. Postmortem redistribution of Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Forensic Sci Int. 2011;212:247–51.CrossRef
9.
go back to reference Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107:1277.CrossRef Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107:1277.CrossRef
10.
go back to reference Huestis MA. Cannabis-impaired driving: a public health and safety concern. Clin Chem. 2015;61:1223–5.CrossRef Huestis MA. Cannabis-impaired driving: a public health and safety concern. Clin Chem. 2015;61:1223–5.CrossRef
11.
go back to reference Turnbull D, Hodge JG. Driving under the influence of marijuana laws and the public's health. J Law Med Ethics. 2017;45:280–3.CrossRef Turnbull D, Hodge JG. Driving under the influence of marijuana laws and the public's health. J Law Med Ethics. 2017;45:280–3.CrossRef
12.
go back to reference Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem. 2013;59:519–26.CrossRef Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem. 2013;59:519–26.CrossRef
13.
go back to reference Armentano P. Should per se limits be imposed for cannabis? Equating cannabinoid blood concentrations with actual driver impairment: practical limitations and concerns. HJSR. 2013:45–55. Armentano P. Should per se limits be imposed for cannabis? Equating cannabinoid blood concentrations with actual driver impairment: practical limitations and concerns. HJSR. 2013:45–55.
14.
go back to reference Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491–3.CrossRef Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491–3.CrossRef
15.
go back to reference Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther. 1996;34:446–52.PubMed Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther. 1996;34:446–52.PubMed
16.
go back to reference Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34:352–63.CrossRef Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34:352–63.CrossRef
17.
go back to reference Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retrovir. 1997;13:305–15.CrossRef Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retrovir. 1997;13:305–15.CrossRef
18.
go back to reference Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep. 1984;68:1427–31.PubMed Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep. 1984;68:1427–31.PubMed
19.
go back to reference Drummer OH. Postmortem toxicology of drugs of abuse. Forensic Sci Int. 2004;142:101–13.CrossRef Drummer OH. Postmortem toxicology of drugs of abuse. Forensic Sci Int. 2004;142:101–13.CrossRef
20.
go back to reference Lemos NP, Ingle EA. Cannabinoids in postmortem toxicology. J Anal Toxicol. 2011;35:394–401.CrossRef Lemos NP, Ingle EA. Cannabinoids in postmortem toxicology. J Anal Toxicol. 2011;35:394–401.CrossRef
21.
go back to reference Olson KN, Luckenbill K, Thompson J, Middleton O, Geiselhart R, Mills KM, et al. Postmortem redistribution of fentanyl in blood. Am J Clin Pathol. 2010;133:447–53.CrossRef Olson KN, Luckenbill K, Thompson J, Middleton O, Geiselhart R, Mills KM, et al. Postmortem redistribution of fentanyl in blood. Am J Clin Pathol. 2010;133:447–53.CrossRef
22.
go back to reference Bosker WM, Karschner EL, Lee D, Goodwin RS, Hirvonen J, Innis RB, et al. Psychomotor function in chronic daily Cannabis smokers during sustained abstinence. PLoS One. 2013;8:e53127.CrossRef Bosker WM, Karschner EL, Lee D, Goodwin RS, Hirvonen J, Innis RB, et al. Psychomotor function in chronic daily Cannabis smokers during sustained abstinence. PLoS One. 2013;8:e53127.CrossRef
23.
go back to reference Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney GR, et al. Effect of blood collection time on measured delta9-tetrahydrocannabinol concentrations: implications for driving interpretation and drug policy. Clin Chem. 2016;62:367–77.CrossRef Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney GR, et al. Effect of blood collection time on measured delta9-tetrahydrocannabinol concentrations: implications for driving interpretation and drug policy. Clin Chem. 2016;62:367–77.CrossRef
24.
go back to reference Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16:276–82.CrossRef Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16:276–82.CrossRef
25.
go back to reference Andrews R, Murphy KG, Nahar L, Paterson S. Cannabinoid concentrations detected in fatal road traffic collision victims compared with a population of other postmortem cases. Clin Chem. 2015;61:1256–64.CrossRef Andrews R, Murphy KG, Nahar L, Paterson S. Cannabinoid concentrations detected in fatal road traffic collision victims compared with a population of other postmortem cases. Clin Chem. 2015;61:1256–64.CrossRef
26.
go back to reference Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev. 2008;40:926–34.CrossRef Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev. 2008;40:926–34.CrossRef
27.
go back to reference Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009;18:185–93.CrossRef Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009;18:185–93.CrossRef
28.
go back to reference Laumon B, Gadegbeku B, Martin JL, Biecheler MB, Group SAM. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005;331:1371.CrossRef Laumon B, Gadegbeku B, Martin JL, Biecheler MB, Group SAM. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005;331:1371.CrossRef
29.
go back to reference Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2013;60:254–67.CrossRef Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2013;60:254–67.CrossRef
Metadata
Title
The pitfalls of per se thresholds in accurately identifying acute cannabis intoxication at autopsy
Authors
Mary K. Schwerdt
James R. Gill
Publication date
01-12-2018
Publisher
Springer US
Published in
Forensic Science, Medicine and Pathology / Issue 4/2018
Print ISSN: 1547-769X
Electronic ISSN: 1556-2891
DOI
https://doi.org/10.1007/s12024-018-0019-2

Other articles of this Issue 4/2018

Forensic Science, Medicine and Pathology 4/2018 Go to the issue